[REVISION HISTORY]

Advancements in medical AI and diagnostic technology

Updated 13 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-30 19:44 UTC → 2026-10-16 01:52 UTC · added ~~removed~~

Medical technology continues to evolve through the integration of artificial intelligence in oncology, cardiology, and immunotherapy. In cancer research, new AI models are enhancing both screening and treatment prediction. An international team developed Spalmmune, an AI model that predicts patient responses to immune checkpoint inhibitors for melanoma and lung cancer with 92% sensitivity, outperforming conventional biomarkers. Additionally, researchers have identified a molecular mechanism involving the protein RAC1 and SUMOylation that facilitates breast cancer metastasis via invadopodia formation. Lung cancer research has seen further advancements through AI-driven drug discovery and biomarker identification. At Stanford Medicine, researchers used approximately 37,000 AI agents to analyze human drug studies, finding that drugs targeting genes acting as ‘on/off switches’ were significantly more likely to pass Phase 1 trials and reach the market. This methodology has been applied to the study of the B7-H3 protein. Separately, researchers from GENyO, the University of Granada, and the Biosanitary Research Institute of Granada identified the long non-coding RNA TUSC7 as a potential biomarker for non-small cell lung cancer to improve diagnostic precision. In South Korea, researchers at Ajou University Hospital have developed an AI-based imaging biomarker to predict prognosis for non-small cell lung cancer patients undergoing immunotherapy. By analyzing pre-treatment CT scans, the team created a ‘Vascular Risk Score’ (VRS) to quantify blood vessel deformation around tumors; lower VRS values were associated with longer periods without cancer progression and higher survival rates. Furthermore, South Korea’s Health Insurance Review and Assessment Service has expanded insurance coverage for tests predicting immunotherapy responses in gastric cancer patients, specifically for inoperable HER2-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma treated with pembrolizumab and chemotherapy. Diagnostic screening advancements show mixed results. While the PATHFINDER 2 study in the U.S. found the Galleri blood test achieved a positive predictive value of 60.3%, the NHS-Galleri trial in England failed to meet its primary endpoint of reducing late-stage diagnoses. Conversely, a multimodal AI framework at Sun Yat-sen Memorial Hospital in China has achieved high diagnostic accuracy for breast cancer. In cardiology, AI is advancing both diagnostics and procedural support. The U.S.-based company HEARTio is developing ECGio to detect coronary artery disease from standard electrocardiograms in under one minute. Furthermore, Burjeel Hospital in Abu Dhabi has launched the first AI-powered cardiac catheterisation laboratory in the GCC, utilizing digital image-processing to optimize visualization during procedures such as angioplasty and stenting to support clinical planning.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.